Business & Finance RFK Jr.'s peptide policy could boost Hims & Hers as its GLP-1 business evolves
Hims may have a chance to grow peptides business as a potential revenue driver, with FDA review in 2026 shaping the opportunity.
By
· April 16, 2026 · 1 min read
This article was originally published by
CNBC Top News
and is republished here under license.
Hims may have a chance to grow peptides business as a potential revenue driver, with FDA review in 2026 shaping the opportunity.
Like this:
Like Loading...
Related
Why ‘buy the dip’ is Trump Always Chickens Out’s best friend.…
By
· April 22, 2026 · 1 min read
JLL Real Estate Management Services Global CEO Neil Murray believes the long-term Middle East investment thesis remains structurally intact, though…
By
· April 22, 2026 · 1 min read
Latvian central bank governor Mārtiņš Kazāks sees no rush to respond to higher energy prices driven by Iran war…
By
· April 22, 2026 · 1 min read
Leave a Reply